Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
relaxera igf receptor synthetic peptide
- Development stage
- Preclinical
- Lead developer
- Relaxera
- Modality
- Peptides
01
Overview
Relaxera's IGF receptor synthetic peptide is a preclinical-stage therapeutic candidate developed by Relaxera GmbH. The molecule is a synthetic peptide designed to interact with the Insulin-like growth factor (IGF) receptor, a tyrosine kinase receptor that plays a central role in cell growth, proliferation, and survival signaling. Relaxera utilizes its proprietary platform for the chemical synthesis of complex, disulfide-rich peptides to develop stable and potent analogs of human hormones. While specific clinical indications have not been publicly disclosed, IGF receptor modulation is a well-established target for therapeutic intervention in oncology, growth disorders, and metabolic diseases. The asset is currently in the preclinical phase of development.
- Other names
- IGF receptor synthetic peptide
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on relaxera igf receptor synthetic peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on relaxera igf receptor synthetic peptide.